<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111133</url>
  </required_header>
  <id_info>
    <org_study_id>INT/IEC/2019/001617</org_study_id>
    <nct_id>NCT04111133</nct_id>
  </id_info>
  <brief_title>Ivabradine in Cirrhotic Cardiomyopathy</brief_title>
  <official_title>Efficacy of Carvedilol + Ivabradine vs Carvedilol Alone for Left Ventricular Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality; a Prospective Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who
      have been found to have left ventricular diastolic dysfunction on a screening 2D
      echocardiography, will then be randomized by Block randomization technique, to two arms in a
      ratio 1:1(Group A) will receive carvedilol+ Ivabradine targeted therapy for heart rate
      reduction while Group B will receive Carvedilol alone; and the dosage of drug in the
      treatment arm will be titrated every week to achieve target heart rate of 50-60/ minute.
      Patients in the treatment arms, who are unable to tolerate carvedilol due to hypotension
      episodes, will be offered ivabradine alone to allow achievement of targeted heart rate
      reduction. All patients will be evaluated at 0,6, and 12 months. The end points will be
      clinical events, cardiac function improvement, renal function, and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have already demonstrated the role of targeted heart rate reduction in the
      management of LVDD in cirrhosis, but the previous study could not demonstrate the role of
      ivabradine alone in absence of betablocker therapy. This trial will be a validation cohort
      for the initial data obtained on this novel drug. The use of ivabradine can treat patients
      who do not tolerate betablocker therapy due to contraindications or adverse effects
      especially hypotension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Episodes of Cirrhosis related events</measure>
    <time_frame>12 months</time_frame>
    <description>New onset ascites, variceal bleeding,hepatorenal syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality to be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in E/e' Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Improved Echo parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in HRQoL</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in neurohormonal markers- Brain natriuretic peptide, aldosterone, plasma renin activity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cirrhotic Cardiomyopathy</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol + Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betablocker + ivabradine</intervention_name>
    <description>Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute</description>
    <arm_group_label>Carvedilol + Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betablocker</intervention_name>
    <description>Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range of 18-65 years

          -  Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings,

          -  LV diastolic dysfunction on 2D echocardiography

        Exclusion Criteria:

          -  Chronic renal disease

          -  Patient already on beta blocker

          -  Pregnancy and peripartum cardiomyopathy

          -  Hypertension

          -  Coronary artery disease

          -  Valvular heart disease

          -  Sick sinus syndrome/ Pacemaker

          -  Cardiac rhythm disorder

          -  Hypothyroidism

          -  Hyperthyroidism

          -  Portal vein thrombosis

          -  Transjugular intrahepatic porto systemic shunt (TIPS) insertion

          -  Hepatocellular carcinoma

          -  Anemia Hb &lt; 8gm/dl in females, and &lt; 9 gm/dl in males
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radha K Dhiman, MD DM</last_name>
    <role>Study Chair</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhumita Premkumar, MD DM</last_name>
    <phone>01722756344</phone>
    <email>drmadhumitap@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <state>Choose Any State/Province</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhumita Premkumar</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Madhumita Premkumar</investigator_full_name>
    <investigator_title>Assistant Professor and Principal Investigator, Department of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Cirrhotic cardiomyopathy</keyword>
  <keyword>Left ventricular diatolic dysfunction</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Ivabradine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

